"The U.S. Food and Drug Administration today expanded the approved use of the CoreValve System to treat certain patients who have previously had a tissue aortic valve replacement and are in need of a second one.
This first-of-its-kind use is"...
Do not administer DEFINITY® to patients with known or suspected:
- Right-to-left, bi-directional, or transient right-to-left cardiac shunts,
- Hypersensitivity to perflutren [see WARNINGS AND PRECAUTIONS].
Do not administer DEFINITY® by intra-arterial injection.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/31/2015
Additional Definity Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.